

Effects of Whey Proteins on Glucose Metabolism in Normal Wistar Rats and Zucker Diabetic Fatty (ZDF) Rats

Søren Gregersen¹, Sara Bystrup¹, Ann Overgaard¹, Per B. Jeppesen¹, Anne C. Sønderstgaard Thorup¹, Erik Jensen², and Kjeld Hermansen¹

¹ Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Aarhus C, Denmark.

² Arla Foods Ingredients Group P/S, Sønderhøj 10-12, 8260 Viby J, Denmark. Address correspondence to: Søren Gregersen, e-mail: soeren.gregersen@aarhus.rm.dk

Manuscript submitted November 3, 2013; resubmitted December 17, 2013; accepted December 18, 2013

Abstract

BACKGROUND: Beneficial effects of milk protein on glucose metabolism have been reported. **OBJECTIVES:** We hypothesized that dietary supplementation with specific milk protein fractions could prevent diabetes and differentially alter tissue gene expression. Therefore, we studied the effects of supplementing the diet with whey isolate, whey hydrolysate, α -lactalbumin, and casein proteins in Zucker Diabetic Fatty rats (ZDF) and normal Wistar rats. A chow diet was included as well. **METHODS:** Six week old male ZDF (n = 60) and Wistar rats (n = 44) were used in a 13 week study. P-glucose, p-insulin, p-glucagon, HbA1c, total-cholesterol, HDL-cholesterol, and triglycerides were measured. An oral glucose tolerance test (OGTT) was performed. Liver, muscle, and adipose samples were used for RT-PCR. One-way ANOVA and multiple comparison tests were performed. **RESULTS:** HbA1c increased during intervention, and was significantly lower for all milk protein fractions

compared to chow in the ZDF rats ($p < 0.05$). At week 18, iAUCs during OGTT in the ZDF rats were similar for all milk protein-treated groups and significantly lower than in the chow fed group ($p < 0.01$). In the chow-fed group of ZDF rats, p-glucagon increased significantly compared to all milk protein fed animals. Total and HDL cholesterol were increased in the milk protein-treated ZDF rats compared with the control group. Expression of liver GYS2 and SREBP-2 were downregulated in the milk protein-fed ZDF groups compared with chow. **CONCLUSIONS:** We conclude that milk protein fractions improve glycemic indices in diabetic rats. No major differences were seen between the milk protein fractions. However, the fractions had a differential impact on tissue gene expression, most pronounced in ZDF rats.

Keywords: type 2 diabetes · milk protein · whey protein · casein · Zucker rat · Wistar rat · ZDF · glucose tolerance test · OGTT · gene expression

Introduction

The high prevalence and incidence of obesity and type 2 diabetes (T2D) call for new ways to reduce the risk of T2D and cardiovascular disease. Dietary means of preventing the obesity problem is of major importance. Consumption of milk and dairy products has been associated with reduced risk of diabetes [1]. Milk contains two primary sources of protein, casein and whey. Recently, the beneficial physiological effects of whey protein on the control of food intake and glucose

metabolism have been reported [2]. Studies have shown insulinotropic and glucose-lowering properties of whey protein in healthy and T2D subjects [2, 3]. Diets high in whey protein and isolates have therefore been of interest in weight management and as promoters of muscle protein synthesis [4].

We have previously shown that whey protein acutely lowers postprandial triglyceride levels in obese [5] and T2D subjects ingesting a fat-rich meal [6]. Whey protein contains high amounts of branched chain amino acids, β -lactalbumin, α -lactalbumin, immunoglobulins, and albumin [7].

Abbreviations:

ACE - angiotensin-converting enzyme
 ANOVA - analysis of variance
 BW - body weight
 cDNA - complementary DNA
 CPT-1 - carnitine palmitoyltransferase 1
 CRP - C-reactive protein
 Ct - cycle threshold
 DNA - deoxyribonucleic acid
 DNase - deoxyribonuclease
 DPP-4 - dipeptidylpeptidase 4
 GLP-1 - glucagon-like peptide 1
 GLUT-2 - glucose transporter 2
 GYS2 - glycogen synthase 2
 HbA1c - glycosylated hemoglobin
 HDL - high-density lipoprotein
 HOMA-IR - homeostasis model assessment - insulin resistance
 HPRT1 - hypoxanthine phosphoribosyltransferase 1
 iAUC - incremental area under the curve
 IL-6 - interleukin 6
 InsR - insulin receptor
 IR - insulin resistance
 JNK - c-Jun N-terminal kinase
 OD - optical density
 OGTT - oral glucose tolerance test
 PGC-1 α - PPAR gamma coactivator 1 alpha
 PPAR - peroxisomal proliferators-activated receptor
 RIA - radioimmunoassay
 RNA - ribonucleic acid
 RT-PCR - real-time polymerase chain reaction
 SD - standard deviation
 SEM - standard error of mean
 SREBP-2 - sterol regulatory element-binding protein 2
 T2D - type 2 diabetes
 TNF- α - tumor necrosis factor alpha
 ZDF - Zucker Diabetic Fatty (rat)

The potential of specific milk protein fractions to prevent T2D needs clarification. Furthermore, our knowledge is sparse on how the different protein fractions modulate tissue-specific key regulatory genes involved in glucose- and lipid-metabolism as well as inflammation.

We hypothesized that enrichment of the diet with various milk protein fractions can postpone the progression of diabetes. To study this hypothesis we compared the effects of whey isolate, whey hydrolysate, α -lactalbumin, and casein and also included a standard chow diet in Zucker Diabetic Fatty (ZDF) and normal Wistar rats in a 13-week intervention study.

Materials and methods

Design

In the diet intervention study, we used 6 week old animals, 60 male ZDF rats and 44 male Wistar

rats (control). ZDF rats were used for the study of T2D; they have a leptin receptor mutation [8]. Before intervention, rats were fed a standard chow diet (Altromin 1324, Altromin GmbH, Lage, Germany). The two rat strains were each divided into five intervention groups (n = 12/group for ZDF rats, n = 8-9/group for Wistar rats):

1. Whey protein isolate
2. Whey protein hydrolysate
3. α -lactalbumin
4. Casein
5. Standard chow (1324, Altromin, Lage, Germany)

The animals were housed in individual cages at 21°C, with a 12-hour light:dark cycle. The experiment was performed in accordance with the Danish Animal Ethics Council.

Blood sampling was conducted before and at the end of the experiments, and blood glucose, body weight, and 24-hour food intake were measured every fortnight.

During the last week of the intervention an oral glucose tolerance test (OGTT) was performed. At the end of the intervention, animals were sacrificed, and blood and tissue samples were taken for hormone and plasma lipid examinations and gene expression studies.

Diets

The whey and casein protein fractions were provided by Arla Foods Ingredients Group P/S (Viby J, Denmark) and incorporated into pellets by Altromin (Lage, Germany). We applied the following three different whey protein fractions:

1. Whey protein isolate
2. Whey protein hydrolysate
3. α -lactalbumin

Hereafter, the fractions are referred to as isolate, hydrolysate, and α -lactalbumin.

The macronutrient composition of the diets is shown in **Table 1**. A macronutrient analysis was performed by the Danish Veterinary and Food Administration, Region Nord. The relative composition of macronutrients and energy densities were close to similar in the protein groups, whereas the chow group had higher carbohydrate and lower protein content as intended. The standard chow was 1324 from Altromin containing 19% crude protein.

Table 1. Macronutrient composition (unit/100g) of the five experimental diets used in the intervention study

| Component/ energy | Whey protein | | | Casein | Chow |
|----------------------|--------------|-----------|--------------------|--------|------|
| | Isolate | Hydrolys. | α -lactalb. | | |
| Carbohydrate (g) | 41.1 | 45.1 | 42.2 | 41.2 | 53.0 |
| Protein (g) | 48.6 | 42.4 | 49.1 | 49.0 | 19.0 |
| Fat (g) | 5.1 | 5.1 | 6.1 | 5.8 | 4.0 |
| Energy (kJ) | 1680 | 1646 | 1739 | 1709 | 1344 |

Blood sampling

Blood samples were collected from the tip of the tail at week 6. Chilled tubes containing a 3 μ l mix of aprotinin/heparin (7.7 mg/ml / 2.300 IU/ml) were used. Samples were immediately centrifuged (4.000 rpm, 10 minutes, 4°C), and plasma was collected and frozen for later analysis of plasma (p)-glucose, p-insulin, p-glucagon, total-cholesterol, HDL-cholesterol, and triglycerides. Whole blood was collected separately in ethylenediamine-tetraacetic acid-preserved collection tubes for hemoglobin A1c (HbA1c) analysis.

Oral glucose tolerance test

At week 18, an OGTT was performed after a 12-hour fast. D-glucose was administered via an oral gavage tube (2 g/kg body weight (BW)). Whole blood sampled from the tail was analyzed on a glucose meter (OneTouch Precision Xceed, Abbott Laboratories A/S, Denmark) at time points -15, 0, 30, 60, 90, 120, and 180 minutes. The trapezoidal method was applied for calculation of the incremental area under the curve (iAUC) for glucose measurements obtained at the OGTT [9].

HOMA-IR

As a surrogate measure of insulin sensitivity we applied the HOMA-IR model using the equation $\text{HOMA-IR} = \text{fasting p-glucose (mM)} \times \text{fasting p-insulin (mU/l)} / 22.5$. The equation is considered to be a predictor of total body insulin sensitivity also in rats [10].

Tissue sampling

At the end of the intervention study (week 19) the animals were anaesthetized using pentobarbital (50 mg/kg BW), and blood sampling was performed in the animals via the intra-orbital plexus for (same samples as week 6). After cervical dislo-

cation a midline laparotomy was performed in order to obtain liver and adipose samples. A muscle sample was taken from the soleus muscle on both hind legs. All tissue samples were frozen immediately in liquid nitrogen for subsequent gene expression studies.

Gene expression analyses

Real-time (RT) polymerase chain reaction (PCR) was performed on liver, adipose and muscle tissue.

Tissue samples (20 mg liver, 100 mg fat, 30 mg muscle) were homogenized using tissue specific Qiagen RNeasy Kits on a Qiacube (Qiagen, Copenhagen, Denmark) according to manufacturer's instructions and RNA purification using RNeasy spin columns. Traces of genomic DNA were removed by DNase treatment. Quality control was performed using optical density (OD) measurements and gel electrophoresis.

Hereafter, reverse transcription was carried out using iScript™ cDNA synthesis kit (Biorad, Hercules, CA, USA). The RT-PCR was carried out using the TaqMan assays consisting of pre-designed probes and primers. 18S and Hprt1 were used as reference genes. Aros Applied Biotechnology A/S (Skejby, Denmark) performed the RT-PCR on the liver, muscle and adipose tissue using Fluidigm's Biomark™ real-time PCR system (San Francisco, California, USA). A total of 30 specific genes and two reference genes were analyzed in triplicate.

Efficiencies between 80% and 100% and correlation coefficients above 0.995 were accepted. A variation of 5% between the analyses of the same gene was accepted. The relative gene expression was calculated using the $2^{-\Delta\text{Ct}}$ method. This method calculates the relative abundance of each gene based on the average cycle threshold number (Ct) of the triplicates and the geometric mean of the Ct values of the two reference genes (18S and HPRT1).

Analyses

At week 6 and 19, plasma concentrations of glucose, hormones and lipids were determined as follows. Insulin and glucagon were measured using RIA kits for rat insulin and glucagon (Linco Research Inc., St Charles, MO, USA). P-glucose, total cholesterol, HDL-cholesterol, triglyceride, and HbA1c were all analyzed using enzymatic colorimetric methods on a COBAS c111 (Roche Diagnostics Intl. Ltd., Switzerland).

Table 2. Food intake (g) measured during a 24-hour period every second week in the 13 week intervention with milk protein fractions in ZDF and Wistar rats, respectively

| Model | Group | Week | | | | | |
|------------|---------------|---------------------------|-------------------------|-------------------------|-------------------------|---------------------------|---------------------------|
| | | 7 | 9 | 11 | 13 | 15 | 17 |
| ZDF rat | Isolate | 21.8 ± 4.3 | 18.9 ± 2.3 ^g | 20.1 ± 1.7 ^e | 25.7 ± 4.7 ^e | 23.7 ± 2.5 ^d | 20.3 ± 6.3 ^d |
| | Hydrolysate | 22.2 ± 4.2 | 20.6 ± 4.9 ^f | 20.3 ± 7.0 ^f | 25.1 ± 4.9 ^f | 25.2 ± 4.4 ^{d,i} | 20.2 ± 2.7 ^d |
| | α-lactalbumin | 20.7 ± 4.0 ^a | 19.4 ± 2.6 ^g | 20.5 ± 2.5 ^e | 25.0 ± 3.0 ^e | 24.4 ± 2.9 ^h | 19.9 ± 5.6 ^d |
| | Casein | 19.9 ± 2.9 ^b | 18.7 ± 1.4 ^g | 20.4 ± 2.5 ^e | 21.5 ± 2.1 ^g | 19.6 ± 2.0 ^f | 16.2 ± 2.5 ^{d,h} |
| | Chow | 25.9 ± 3.8 | 29.4 ± 3.3 | 27.4 ± 3.3 | 34.6 ± 2.6 | 31.9 ± 3.5 | 33.5 ± 3.6 |
| Wistar rat | Isolate | 19.7 ± 1.8 ^d | 18.7 ± 2.0 ^c | 17.3 ± 2.9 ^d | 16.4 ± 4.1 ^g | 18.5 ± 2.0 ^a | 18.0 ± 1.9 ^a |
| | Hydrolysate | 21.5 ± 3.2 ^{c,j} | 20.5 ± 3.8 ^b | 18.9 ± 2.7 ^c | 19.5 ± 2.8 | 18.2 ± 1.9 ^a | 19.4 ± 2.7 |
| | α-lactalbumin | 17.4 ± 2.1 ^d | 18.6 ± 2.4 ^d | 17.6 ± 2.6 ^d | 17.3 ± 1.7 ^f | 16.9 ± 2.4 ^b | 17.5 ± 2.1 ^b |
| | Casein | 18.2 ± 1.6 ^d | 19.5 ± 3.3 ^c | 19.7 ± 3.6 ^c | 18.2 ± 1.4 ^e | 18.3 ± 2.5 ^a | 18.7 ± 2.4 |
| | Chow | 27.4 ± 3.2 | 28.5 ± 5.6 | 26.6 ± 3.5 | 25.0 ± 1.9 | 22.9 ± 4.7 | 22.4 ± 3.7 |

Legend: Data are means ± SEM, n(ZDF) = 12/group, n(Wistar) = 8-9/group. ^a p < 0.05, ^b p < 0.01, ^c p < 0.001, ^d p < 0.0001 vs. chow (one-way ANOVA). ^e p < 0.05, ^f p < 0.01, ^g p < 0.001 vs. chow (Kruskal-Wallis nonparametric test). ^h p < 0.05, ⁱ p < 0.01 vs. casein (one-way ANOVA). ^j p < 0.05 vs. α-lactalbumin (one-way ANOVA).

Statistics

Statistical tests were performed using GraphPad Prism version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Data were expressed as mean ± SEM, unless stated otherwise. Homogeneity of variances was calculated using Bartlett's test. One-way analysis of variance (ANOVA) was performed to test overall group differences. Hereafter, the multiple comparison test Bonferroni was performed. In cases where the data were not normally distributed, data were logarithmically transformed. If the assumptions were still not met, the nonparametric Kruskal-Wallis test followed by Dunn's multiple comparisons test was applied. P < 0.05 was considered significant.

Results

Food intake and body weight

Twenty-four hour food intake was measured every second week from start to week 17. With the exception of a lower daily food intake for the casein treated group of ZDF rats, the food intake was similar in the other high-protein fed groups. At all points in time, in both ZDF and Wistar rats the chow fed groups had a higher food intake than the high protein fed groups (**Table 2**).

Body weight from start to week 18 is shown in **Table 3**. For both ZDF and Wistar rats no significant differences were observed at week 18.

Plasma and whole blood glucose

The fasting whole blood glucose was measured every second week from the tip of the tail using a portable glucose meter. As can be seen from **Table 4**, there was a gradual increase in the fasting blood glucose for all groups of ZDF animals as expected. The rise in blood glucose was most pronounced for the chow-fed group animals. Overall, the dietary interventions in the Wistar rats did not result in changes in the blood glucose levels.

P-glucose was also measured at the beginning and at the end of the intervention. No significant differences between groups were detected when comparing changes in p-glucose (**Figure 1**).

HbA1c

HbA1c was determined at the start and the end of the intervention. The HbA1c increases (above baseline) are shown in **Figure 2**. For the diabetic rats the chow group showed significantly larger increases during the intervention compared to all other milk protein groups (**Figure 2A**). The casein groups showed the lowest increase in HbA1c compared to all other groups. For the Wistar rats no changes were seen between intervention groups (**Figure 2B**).

OGTT

One week before termination an OGTT was performed. As shown in **Figure 3A** for the ZDF

Table 3. Body weight (g) measured weekly during the 13 week intervention with milk protein fractions in ZDF and Wistar rats, respectively

| Model | Group | Week | | | | | | |
|------------|-----------------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | | 6 | 8 | 10 | 12 | 14 | 16 | 18 |
| ZDF rat | Isolate | 203.0 ± 5.0 | 308.0 ± 11.0 | 370.0 ± 11.0 | 431.0 ± 11.0 | 468.0 ± 10.0 | 498.0 ± 10.0 | 528.0 ± 10.0 |
| | Hydrolysate | 200.0 ± 6.0 | 296.0 ± 13.0 | 365.0 ± 13.0 | 417.0 ± 13.0 | 458.0 ± 13.0 | 493.0 ± 13.0 | 493.0 ± 13.0 |
| | α -lactalbumin | 206.0 ± 6.0 | 298.0 ± 6.0 | 333.0 ± 14.0 | 408.0 ± 6.0 | 454.0 ± 5.0 | 490.0 ± 6.0 | 524.0 ± 9.0 |
| | Casein | 210.0 ± 6.0 | 300.0 ± 13.0 | 344.0 ± 13.0 | 398.0 ± 15.0 | 426.0 ± 16.0 | 447.0 ± 15.0 | 475.0 ± 17.0 |
| | Chow | 206.0 ± 5.0 | 279.0 ± 5.0 | 343.0 ± 6.0 | 392.0 ± 7.0 | 425.0 ± 9.0 | 455.0 ± 11.0 | 485.0 ± 14.0 |
| Wistar rat | Isolate | 195.0 ± 5.0 | 272.0 ± 7.0 | 318.0 ± 8.0 | 347.0 ± 10.0 | 365.0 ± 11.0 | 387.0 ± 12.0 | 404.0 ± 12.0 |
| | Hydrolysate | 198.0 ± 4.0 | 270.0 ± 7.0 | 304.0 ± 14.0 | 351.0 ± 6.0 | 378.0 ± 7.0 | 404.0 ± 8.0 | 423.0 ± 8.0 |
| | α -lactalbumin | 193.0 ± 7.0 | 263.0 ± 7.0 | 315.0 ± 9.0 | 349.0 ± 8.0 | 382.0 ± 7.0 | 407.0 ± 9.0 | 426.0 ± 8.0 |
| | Casein | 198.0 ± 6.0 | 278.0 ± 3.0 | 324.0 ± 3.0 | 348.0 ± 4.0 | 366.0 ± 5.0 | 380.0 ± 6.0 | 392.0 ± 7.0 |
| | Chow | 183.0 ± 6.0 | 275.0 ± 9.0 | 312.0 ± 10.0 | 338.0 ± 12.0 | 355.0 ± 12.0 | 392.0 ± 13.0 | 410.0 ± 11.0 |

Legend: Data are means ± SEM, n(ZDF) = 12/group, n(Wistar) = 8-9/group.

rats the incremental area under the curve (iAUC) was similar for all high protein treated groups. The chow fed group had larger iAUC compared to all high protein diets (**Figure 3A**). No significant differences were observed between iAUCs for the Wistar rats (**Figure 3B**).

Plasma insulin and glucagon

P-insulin and p-glucagon were measured at the beginning and at the end of the intervention. **Figures 4** and **5** show p-insulin and glucagon levels after and before the interventions. For both ZDF and Wistar rats no significant changes for p-insulin were induced by either diet type (**Figures 4A** and **4B**). The change in p-glucagon in the ZDF rats was similar between the protein treated groups and significantly lower than for the chow fed (**Figure 5A**) whereas no changes could be detected for p-glucagon in the Wistar rats (**Figure 5B**).

HOMA-IR

To assess the impact of dairy proteins on insulin resistance HOMA-IR was calculated for both rat types after the intervention. As expected, the HOMA-IR was higher for the ZDF rats (mean 163 ± 10) than for the Wistar rats (mean 30 ± 4). No significant differences between intervention groups were found for HOMA-IR (data not shown).

Plasma lipids

Circulating levels of total cholesterol, HDL-cholesterol and triglycerides were determined at

the beginning and at the end of the intervention. For the ZDF rats, total cholesterol levels increased significantly more in the three whey protein fed groups compared to both casein and chow (**Figure 6A**). Casein and chow did not differ significantly. HDL cholesterol levels seemed to increase in all the protein fed groups compared to chow, but only isolate, hydrolysate and casein showed a statistically significant increase compared to chow (**Figure 6C**). Triglyceride levels increased in all groups. The rise in triglycerides was remarkably higher in the whey fraction groups and chow compared to casein, but only hydrolysate and α -lactalbumin were statistically significantly increased compared to casein (**Figure 6E**).

For normal rats, total cholesterol levels slightly decreased during the intervention with no statistically significant differences between groups (**Figure 6B**). With the exception of the casein group, a small decrease in HDL cholesterol was noticed for all other groups. The decrease in HDL cholesterol was significant in the α -lactalbumin and chow fed groups compared with the casein group. The decrease in the chow group was also statistically larger compared to whey hydrolysate (**Figure 6D**). No significant changes in triglyceride levels were found (**Figure 6F**).

Gene expression

The expression levels of selected genes primarily involved in glucose and lipid metabolism as well as inflammation were studied after the intervention in both ZDF and Wistar rats in liver, muscle and fat tissue, respectively (**Tables A1-A6**, in

Table 4. Fasting blood glucose (mmol/l) taken as tail blood during the dietary intervention with milk protein fractions in ZDF and Wistar rats, respectively

| Model | Group | Week | | | | | |
|------------|-----------------------|------------------------|------------------------|------------------------|------------------------|-----------|-----------|
| | | 8 | 10 | 12 | 14 | 16 | 18 |
| ZDF rat | Isolate | 4.8 ± 0.1 | 4.8 ± 0.2 | 6.0 ± 0.3 | 6.1 ± 0.3 | 6.1 ± 0.3 | 6.6 ± 0.3 |
| | Hydrolysate | 4.1 ± 0.2 | 4.7 ± 0.2 | 5.1 ± 0.2 | 5.1 ± 0.3 | 5.4 ± 0.2 | 5.6 ± 0.2 |
| | α -lactalbumin | 4.7 ± 0.2 ^a | 5.6 ± 0.4 | 5.8 ± 0.5 ^a | 6.4 ± 0.4 | 6.9 ± 0.5 | 7.4 ± 0.9 |
| | Casein | 5.1 ± 0.1 | 4.5 ± 0.2 | 5.9 ± 0.3 | 5.1 ± 0.1 | 5.8 ± 0.4 | 5.7 ± 0.2 |
| | Chow | 4.4 ± 0.2 | 4.4 ± 0.1 | 5.1 ± 0.3 | 5.8 ± 0.5 | 7.0 ± 1.0 | 8.1 ± 1.0 |
| Wistar rat | Isolate | 4.9 ± 0.3 ^b | 4.3 ± 0.2 | 3.9 ± 0.2 | 4.0 ± 0.1 | 4.2 ± 0.2 | 4.2 ± 0.2 |
| | Hydrolysate | 4.3 ± 0.1 ^c | 4.6 ± 0.3 | 4.2 ± 0.1 | 4.0 ± 0.1 | 4.1 ± 0.1 | 4.1 ± 0.2 |
| | α -lactalbumin | 4.0 ± 0.3 | 4.5 ± 0.2 ^a | 4.6 ± 0.2 | 4.4 ± 0.4 ^d | 4.1 ± 0.1 | 4.4 ± 0.2 |
| | Casein | 4.3 ± 0.2 | 3.8 ± 0.3 | 3.7 ± 0.2 | 3.9 ± 0.3 | 3.6 ± 0.3 | 3.8 ± 0.2 |
| | Chow | 5.2 ± 0.2 | 3.8 ± 0.1 | 4.1 ± 0.2 | 4.0 ± 0.2 | 4.0 ± 0.2 | 4.3 ± 0.2 |

Legend: Data are means ± SEM, n(ZDF) = 12/group, n(Wistar) = 8-9/group. ^a p < 0.05 vs. chow (one-way ANOVA). ^b p < 0.05 vs. hydrolysate (one-way ANOVA). ^c p < 0.01 vs. chow (one-way ANOVA). ^d p < 0.05 vs. casein (Kruskal-Wallis nonparametric test).

the Appendix). Several gene expression changes were observed in all tissues. Fewest gene changes were found in muscle tissue. Compared to chow there was a tendency towards lower InsR and GLUT-2 expression levels. This was, however, only significant for the α -lactalbumin group for InsR and the casein group for GLUT-2. Because of low expression of TNF- α in muscle and liver tissue in ZDF and Wistar rats, and PGC-1 α in liver in ZDF rats, these genes are not shown in **Tables A1-A6** (in the Appendix).

In general, few genes in Wistar rats showed significant changes. Several gene changes were however seen in the adipose tissue of Wistar rats (**Table A6**). The expression level of GLUT-4 in adipose tissue in the α -lactalbumin and casein group was higher compared with the chow group. In addition, CPT-1 expression levels were higher in the α -lactalbumin and casein groups compared to the chow group. Expression levels of FAS were higher expressed in the casein group also compared with the chow group.

Discussion and conclusions

Our study performed in both prediabetic ZDF and normal Wistar rats showed differential effects on metabolism and gene expression levels of the milk protein fractions studied. The main focus of our study was to clarify if particular milk protein fractions had the potential to affect the development and progression of diabetes in a rat model. In parallel, we compared our results in ZDF rats with those obtained in normal Wistar rats to dissect po-

tential effects not influenced by the metabolic disturbances seen in diabetes.

In this study, the main finding was that HbA1c was lower and the glucose tolerance was increased after addition of all milk protein types given to ZDF rats, especially in the casein group. We also compared the impact of the milk protein with that of a standard chow diet. Considerable evidence indicates that milk proteins are beneficial for human health [1]. The mechanisms of action of milk protein fractions may be related to e.g. changes in circulating amino acid levels, ACE inhibition [11] and/or DPP-4 inhibition [12].

None of the milk protein fractions had long-term influences on glycemic control in our non-diabetic rats, as estimated by the lack of effects on HbA1c. In contrast, the HbA1c change (i.e. the difference between level after to level before milk protein supplementation) was significantly lower for all milk protein fractions compared with chow in the ZDF rats. Surprisingly, it occurs that the casein fraction was most potent in this respect. This was unexpected since several previous studies have shown beneficial effects of whey protein compared to casein or other protein types [3, 13-15]. The reason for this could be the substantially lower body weight in the casein treated groups. However, this difference was not statistically significant.

In view of the relatively short intervention period, the OGTT results may provide a more reliable measure of the current glycemic state than HbA1c. Thus, the rats may not have had overt diabetes until a few weeks prior to the study end.




Figure 1. Changes in p-glucose. P-glucose (mmol/l) measured at baseline and after 13 weeks of intervention with four different milk protein fractions (whey isolate, whey hydrolysate, α -lactalbumin, and casein) and chow in ZDF (A) and Wistar (B) rats. The change from baseline to end is calculated and shown in percentage. Data are shown as means \pm SEM, n (ZDF) = 12/group and n (Wistar) = 8-9/group.

Furthermore, all milk protein groups had significantly lower iAUC after an OGTT than the control group. Although the change in whole blood glucose was not significant, the trend towards an improvement in glycemia supports the HbA1c results. The Wistar rats had similar OGTT responses in all groups. In ZDF rats, the OGTT results seemed to correlate well with the HbA1c results. However, the casein group did not have lower iAUC during OGTT, which may reflect a

similar glucose tolerance as the whey protein groups, despite differences in HbA1c. The reason for this apparent discrepancy is not clear.

The results of the HbA1c and OGTT indicate that the progression of diabetes in the whey and casein treated groups is delayed compared with the ZDF control group. Our results corroborate previous studies in high-fat fed mice where a whey protein diet was able to slow diabetes progression [16].




Figure 2. Changes in hemoglobin A1c. Effects on HbA1c of 13 weeks dietary intervention with four different milk protein fractions (whey isolate, whey hydrolysate, α -lactalbumin, and casein) and chow in ZDF (A) and Wistar (B) rats. Data are shown as means \pm SEM, n (ZDF) = 12/group and n (Wistar) = 8-9/group. * $p < 0.05$ and **** $p < 0.0001$ (one-way ANOVA).




Figure 3. Evaluation of oral glucose tolerance test responses after 13 weeks of intervention. Effects on incremental areas under the curve (iAUC) for p-glucose measured by an OGTT after 13 weeks of dietary intervention with four different milk protein fractions (whey isolate, whey hydrolysate, α -lactalbumin, and casein) and chow in ZDF (A) and Wistar (B) rats. Data are shown as means \pm SEM, n(ZDF) = 12/group and n(Wistar) = 8-9/group. ** $p < 0.01$ and **** $p < 0.0001$ (one-way ANOVA).

Surprisingly, neither p-insulin nor HOMA-IR were significantly changed by milk protein fractions in ZDF and Wistar rats. However, other long-term studies have shown that whey intake compared to other protein sources increases insulin sensitivity in humans [17]. Similarly, whey protein compared with no protein had beneficial effects on insulin sensitivity in mice [16]. Our HOMA-IR measurements did not confirm this. However, the HbA1c and OGTT data both indicated an im-

provement of glycemia in ZDF rats receiving milk proteins.

We detected significantly lower p-glucagon levels in all four milk protein groups compared with the ZDF control group. A similar pattern, although not significant, was found in normal rats. It can be speculated that milk proteins have a beneficial effect on p-glucagon levels, leading to reduced glycemia secondary to increased glucagon like peptide 1 (GLP-1), either stimulated via amino acids *per se*




Figure 4. Changes in p-insulin. ZDF (A) and Wistar (B) rats after 13 weeks of dietary intervention with four different milk protein fractions (whey isolate, whey hydrolysate, α -lactalbumin, and casein) and chow. Data are shown as means \pm SEM, n(ZDF) = 12/group and n(Wistar) = 8-9/group.




Figure 5. Changes in p-glucagon. ZDF (A) and Wistar (B) rats after 13 weeks of dietary intervention with four different milk protein fractions (whey isolate, whey hydrolysate, α -lactalbumin, and casein) and chow. Data are shown as means \pm SEM, $n(\text{ZDF}) = 12/\text{group}$ and $n(\text{Wistar}) = 8\text{-}9/\text{group}$. * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$. **** $p < 0.0001$ (one-way ANOVA).

or via inhibition of dipeptidyl peptidase-4 (DPP-4). In the present study, we have not measured changes in circulating amino acids, GLP-1, or DPP-4 inhibition.

Both fasting insulin and glucose levels were profoundly elevated in all ZDF groups by week 13 of the intervention. This indicated the development of severe insulin resistance in muscle and adipose tissue as well as reduced liver glycogen synthesis and storage. In the present study, only fasting insulin levels were measured. It would however also be of interest to measure postprandial insulin levels since increased postprandial insulin levels in response to whey protein have been reported in healthy and T2D subjects [14, 18, 19]. Although similar fasting insulin levels were found in all groups, it cannot be ruled out that stimulated insulin responses may have differed between groups.

When analyzing the metabolic data, one needs to consider food intake and body weight. It is evident that for both ZDF and Wistar rats the food intake was much higher in the control group of rats during the entire intervention. The food intake in the leptin-deficient ZDF rats was, as expected, higher than for normal rats, and the ZDF rats had a higher weight at the end of the intervention period. In contrast, changes in body weight were not seen in Wistar rats. ZDF rats showed different developments in body weight, with the casein and control group showing the lowest body weight rise at the end of the study, despite a

higher food intake for the control group. Most likely, the control group had more severe glucosuria and loss of energy than the milk protein groups. However, this cannot account for the lower body weight in the casein-treated group. It can instead be explained by a significantly lower food intake in the casein group, which may be due to higher satiety caused by coagulated casein in the stomach.

Whether casein induced a lower food intake via increased satiety or thermogenic effect is speculative, especially in ZDF rats. In this context, it has previously been shown that a casein-based diet in rats resulted in lower weight gain compared with a whey diet, despite absence of differences in food intake. This has been explained by the lower nutritional quality of casein protein vs. whey protein [20, 21]. However, it is noteworthy that differences in protein quality did not affect weight gain in normal Wistar rats. Therefore, it is unlikely that differences in weight gain in ZDF rats can be ascribed to differences in protein quality. The energy density in the chow diet was lower (1344 kJ/100 g) than in the protein-enriched groups (1646-1739 kJ/100 g). It cannot be excluded that protein overload in the milk protein groups may had an effect on the results obtained in this study, especially when comparing with the chow group. The study was not designed to test this aspect.

Taken together, our results indicate that all studied milk protein fractions exert beneficial effects in glucose metabolism, with casein mediating




Figure 6. Change in lipid profile after 13 weeks of intervention. Effect of 13 weeks dietary intervention with whey isolate, whey hydrolysate, α -lactalbumin, casein, and chow on changes in total cholesterol, HDL-cholesterol, and triglycerides in ZDF (A, C, E) and Wistar (B, D, F) rats. Data are shown as means \pm SEM, n (ZDF) = 12/group and n (Wistar) = 8-9/group. * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$. **** $p < 0.0001$ (one-way ANOVA). † $p < 0.01$. †† $p < 0.001$ (Kruskal-Wallis nonparametric test).

lowered HbA1c and improved glucose tolerance. In diabetic animals, improved glucose metabolism has probably been mediated by reduced food intake and lowered p-glucagon.

We found an increase in total cholesterol and HDL cholesterol in the milk protein-treated ZDF

rats compared with control. Due to great variations in HDL and triglyceride data we were unable to carry out specific statistical analysis. However, it is noteworthy that casein seemed to suppress triglyceride levels. Increased HDL cholesterol and lowered triglycerides are considered to be benefi-

cial for cardiovascular risk. No major effects on lipid levels were found in the normal Wistar rats. However, HDL cholesterol was lower in the control and α -lactalbumin groups than in the casein group.

We measured gene expression changes in liver, fat, and muscle tissues to identify potential actions of the dietary milk proteins on tissue-specific key regulatory genes involved in insulin sensitivity, inflammation, glucose and fat metabolism, and transcription factors. It is noteworthy that few gene expression changes took place in normal rats, especially in liver and muscle tissue. On the other hand, there were considerably more gene expression changes in the ZDF rats. It is not known whether the observed gene expression changes are the cause or the result of alterations in glycemia and/or the observed changes in circulating lipid levels or other substances.

The finding that liver GYS2 levels were reduced in the milk protein-fed ZDF rats is consistent with the lower circulating glucose levels, presumably resulting in lower liver glycogen synthesis [22]. Furthermore, one may speculate that the net result of lowered GYS2 and lower glucagon levels can lead to reduced hepatic glucose production. Hyperglucagonemia seems to play a major role in hyperglycemia in T2D, as demonstrated by Unger *et al.* [23]. All groups had similar levels of circulating insulin. Under normal conditions, insulin suppresses glucagon secretion once released from the islet β -cells. It is likely that the α -cells have become insensitive to the inhibitory effects of insulin as a result of the diabetic state [24].

In relation to genes involved in inflammation, we studied liver CRP, IL-6, and TNF- α gene expression. In liver, CRP gene expression was significantly lower in the casein group than in the control group, whereas both the isolate and hydrolysate induced higher CRP gene expression levels. No changes were seen in the inflammatory genes in either muscle or fat tissue. As expected, the highest levels of TNF- α were found in fat tissue. No differences were seen between groups. IL-6 also showed low expression levels without group differences. TNF- α and IL-6 can cause insulin resistance by activation of JNK1, and thus interrupting insulin signaling [25]. Therefore, it is surprising that the lowest level of JNK1 expression in adipose tissue was seen in the control group; other studies have found a consistent association between JNK1 and insulin resistance [26]. As mentioned previously, we expected the ZDF control group to be most insulin-resistant. It is possible that the low level of JNK1 gene expression in the control group

is a response variable not solely depending on the inflammatory status.

Adiponectin levels were shown to be inversely correlated with insulin resistance [27]. The present study found a higher adiponectin expression level in the adipose tissue of ZDF animals from the casein group. The findings that the casein- and control-fed groups had comparable body weights, and that a higher adiponectin level was seen in the casein group, pointed to increased insulin sensitivity. Earlier studies have shown that whey protein-, casein-, or high carbohydrate-rich diet have no effect on the circulating levels of adiponectin in obese subjects [28].

We found lower gene expression levels of CRP in the liver of casein-treated ZDF rats. This was in accordance with the finding of lower expression of adiponectin in the casein group. Casein seems to lower inflammation in liver and fat tissue, which may be related to an improved diabetes status. However, it is not possible to distinguish the impact of the lower weight in the casein group from that of "direct" beneficial effects of casein on metabolism and inflammation.

Several transcription factors were differentially expressed. Again, casein seemed to induce the most potent changes, at least in fat expression of e.g. the four important transcription factors PPAR- α , PPAR- γ , JNK, and SREBP-1C. In muscle, expression levels of transcription factors PPAR- γ and SREBP-1C were also increased in most milk protein-fed groups.

One may speculate that milk protein differentially changes gene expression levels towards a more beneficial metabolism in the milk protein groups compared with control. This seems to be most prominent in fat tissue. On the other hand, one may have expected that the metabolically more active tissues, i.e. liver and muscle tissue, would have been more sensitive to changes in circulating amino acid levels than adipose tissue. Therefore, it can be hypothesized that gene expression changes probably induced by milk proteins are particularly important for the fat tissue and may be involved in the redistribution or loss of adipose tissue.

Whey protein seems to induce its beneficial effects via amino acids generated during its gastrointestinal digestion. These amino acids and peptides stimulate the release of several gut hormones such as cholecystokinin, peptide YY, and the incretins gastric inhibitory peptide and glucagon-like peptide 1 that potentiate insulin secretion from β -cells and are associated with regulation of food in-

take. The bioactive peptides also generated from whey protein may serve as endogenous inhibitors of DPP-4 in the proximal gut, preventing incretin degradation. Indeed, DPP-4 inhibitors were recently identified in whey protein hydrolysates. However, our study was not designed to test this. The lower glucagon levels found in all milk protein groups may be ascribed to increased GLP-1 levels which reduced glucagon and thereby lowered glucose production from the liver.

In conclusion, supplementing diet with milk protein fractions may improve glycemic indices in diabetic rats. The milk protein fractions had a dif-

ferential impact on gene expression in normal and diabetic rats.

Acknowledgments: We thank Lene Trudsø, Dorthe Rasmussen and Tove Skrumsager for their skilled technical assistance. The study presented in this article received grants and financial support from Arla Food Ingredients Groups P/S and Aarhus University.

Disclosure: Erik Jensen is employed at Arla Food Ingredients. Arla Foods have provided the milk protein fractions and a study grant to the project. The remaining authors declare no conflicts of interest.

■ Appendix

Table A1. Gene expression levels of selected genes in liver tissue of ZDF rats after 13 weeks of intervention with milk protein fractions

| Gene | Experimental diet | | | | |
|----------------------------|--------------------------------|-------------------------------|------------------------------|-------------------------------|------------------|
| | Isolate | Hydrolysate | α -lactalbumin | Casein | Chow |
| <i>Insulin sensitivity</i> | | | | | |
| InsR | 0.27 \pm 0.09 | 0.25 \pm 0.11 | 0.21 \pm 0.07 ^c | 0.25 \pm 0.06 | 0.33 \pm 0.12 |
| GLUT2 | 6.06 \pm 1.30 | 6.46 \pm 1.24 | 5.32 \pm 1.00 | 5.10 \pm 1.13 ^c | 6.65 \pm 1.22 |
| CPT-1 | 6.60 \pm 2.12 ^f | 6.52 \pm 2.11 | 4.10 \pm 1.38 | 6.13 \pm 1.12 | 5.40 \pm 2.06 |
| Irs1 | 0.16 \pm 0.04 | 0.14 \pm 0.05 | 0.14 \pm 0.05 | 0.15 \pm 0.04 | 0.16 \pm 0.05 |
| Irs2 | 0.24 \pm 0.07 | 0.22 \pm 0.08 | 0.20 \pm 0.07 | 0.20 \pm 0.06 | 0.25 \pm 0.11 |
| AKT | 1.34 \pm 0.34 | 1.18 \pm 0.26 | 1.03 \pm 0.40 | 1.07 \pm 0.22 | 1.19 \pm 0.32 |
| AMPK | 1.05 \pm 0.25 | 0.93 \pm 0.28 | 0.84 \pm 0.20 | 1.03 \pm 0.26 | 1.15 \pm 0.30 |
| AdipoR | 0.42 \pm 0.14 | 0.36 \pm 0.13 | 0.32 \pm 0.10 | 0.37 \pm 0.10 | 0.46 \pm 0.16 |
| <i>Inflammation</i> | | | | | |
| CRP | 26.35 \pm 2.41 ^b | 22.69 \pm 4.40 ^a | 22.50 \pm 3.93 | 18.51 \pm 2.13 ^e | 24.82 \pm 3.04 |
| <i>Glucose</i> | | | | | |
| GYS2 | 0.57 \pm 0.16 | 0.58 \pm 0.11 | 0.42 \pm 0.11 ^g | 0.53 \pm 0.12 | 0.83 \pm 0.31 |
| GADPH | 15.89 \pm 4.00 ^a | 13.65 \pm 2.20 | 13.21 \pm 3.06 | 11.49 \pm 1.94 | 13.15 \pm 4.10 |
| G6Pase | 6.65 \pm 3.63 | 9.84 \pm 5.54 | 7.95 \pm 3.82 | 7.86 \pm 2.90 | 11.04 \pm 5.44 |
| <i>Transcription</i> | | | | | |
| SREBP-1C | 2.87 \pm 1.32 ^{a,c} | 2.21 \pm 0.80 | 2.16 \pm 1.02 | 1.65 \pm 0.65 | 1.51 \pm 1.03 |
| SREBP-2 | 0.31 \pm 0.06 ^f | 0.28 \pm 0.07 ^c | 0.21 \pm 0.06 ^e | 0.26 \pm 0.06 ^d | 0.38 \pm 0.12 |
| PPAR- α | 2.00 \pm 0.73 | 1.59 \pm 0.52 | 1.28 \pm 0.47 | 1.58 \pm 0.55 | 1.87 \pm 0.76 |
| PPAR- γ | 0.01 \pm 0.01 | 0.01 \pm 0.00 | 0.01 \pm 0.00 | 0.01 \pm 0.00 | 0.01 \pm 0.01 |
| JNK | 0.73 \pm 0.16 | 0.70 \pm 0.18 | 0.60 \pm 0.15 | 0.64 \pm 0.13 | 0.77 \pm 0.21 |
| <i>Fat</i> | | | | | |
| FAS | 1.02 \pm 0.39 | 0.85 \pm 0.59 | 0.54 \pm 0.16 | 0.60 \pm 0.35 | 0.79 \pm 0.59 |
| LPL | 0.03 \pm 0.01 | 0.03 \pm 0.01 | 0.03 \pm 0.03 | 0.02 \pm 0.01 | 0.03 \pm 0.01 |
| LXR | 2.24 \pm 0.66 | 1.91 \pm 0.70 | 1.64 \pm 0.34 | 1.93 \pm 0.40 | 2.17 \pm 0.59 |

Legend: Data are means \pm SD; n(ZDF) = 12/group, arbitrary units normalized to the geometric mean of 18S and Hprt1, and multiplied by 100. ^a p < 0.05, ^b p < 0.0001 vs. casein (one-way ANOVA). ^c p < 0.05, ^d p < 0.01, ^e p < 0.0001 vs. chow (one-way ANOVA). ^f p < 0.05 vs. α -lactalbumin (one-way ANOVA). ^g p < 0.05 vs. chow (Kruskal-Wallis nonparametric test).

Table A2. Gene expression level of selected genes in muscle tissue of ZDF rats after 13 weeks of intervention with milk protein fractions

| Gene | Experimental diet | | | | |
|----------------------------|--------------------------------|-------------------|------------------------------|------------------------------|-------------------|
| | Isolate | Hydrolysate | α -lactalbumin | Casein | Chow |
| <i>Insulin sensitivity</i> | | | | | |
| AdipoqR | 1.85 \pm 0.53 ^d | 1.50 \pm 0.41 | 1.30 \pm 0.21 | 1.41 \pm 0.39 | 1.57 \pm 0.37 |
| IR (InsR) | 0.46 \pm 0.14 | 0.51 \pm 0.12 | 0.56 \pm 0.11 | 0.55 \pm 0.11 | 0.53 \pm 0.15 |
| Irs1 | 0.48 \pm 0.21 | 0.49 \pm 0.15 | 0.59 \pm 0.17 | 0.55 \pm 0.13 | 0.39 \pm 0.10 |
| Irs2 | 2.38 \pm 1.88 | 2.26 \pm 1.43 | 3.72 \pm 2.41 | 2.51 \pm 1.93 | 2.87 \pm 2.50 |
| AKT | 5.41 \pm 1.05 | 5.07 \pm 0.68 | 4.86 \pm 0.69 | 4.95 \pm 0.54 | 5.68 \pm 0.56 |
| GLUT4 | 8.77 \pm 2.39 | 8.39 \pm 1.45 | 7.39 \pm 1.57 | 8.77 \pm 1.59 | 8.06 \pm 1.10 |
| AMPK | 3.55 \pm 1.61 | 2.88 \pm 1.32 | 2.18 \pm 0.35 | 2.60 \pm 1.39 | 2.95 \pm 13.30 |
| CPT-1 | 0.13 \pm 0.04 | 0.12 \pm 0.03 | 0.12 \pm 0.03 | 0.11 \pm 0.02 | 0.12 \pm 0.04 |
| <i>Glucose</i> | | | | | |
| GADPH | 132.90 \pm 77.28 | 99.29 \pm 69.24 | 61.76 \pm 10.95 | 94.67 \pm 63.61 | 81.83 \pm 69.58 |
| <i>Transcription</i> | | | | | |
| PGC-1 α | 0.41 \pm 0.26 | 0.33 \pm 0.13 | 0.65 \pm 0.30 | 0.43 \pm 0.18 | 0.65 \pm 0.50 |
| PPAR- γ | 0.04 \pm 0.01 ^b | 0.04 \pm 0.01 | 0.04 \pm 0.01 | 0.03 \pm 0.01 | 0.03 \pm 0.01 |
| PPAR- α | 0.54 \pm 0.17 | 0.57 \pm 0.12 | 0.61 \pm 0.16 | 0.62 \pm 0.14 | 0.63 \pm 0.20 |
| SREBP-1C | 0.74 \pm 0.19 | 0.75 \pm 0.35 | 0.98 \pm 0.18 ^c | 0.96 \pm 0.25 ^c | 0.57 \pm 0.17 |
| JNK | 0.98 \pm 0.18 | 0.94 \pm 0.14 | 0.89 \pm 0.16 | 0.86 \pm 0.10 | 1.02 \pm 0.09 |
| SREBP-2 | 0.41 \pm 0.10 | 0.37 \pm 0.05 | 0.34 \pm 0.04 | 0.33 \pm 0.09 | 0.36 \pm 0.06 |
| <i>Fat</i> | | | | | |
| LXR | 0.21 \pm 0.10 ^{a,d} | 0.15 \pm 0.05 | 0.11 \pm 0.02 | 0.13 \pm 0.05 | 0.13 \pm 0.05 |
| FAS | 0.04 \pm 0.02 | 0.05 \pm 0.04 | 0.04 \pm 0.03 | 0.03 \pm 0.01 | 0.03 \pm 0.01 |
| LPL | 18.75 \pm 8.27 | 24.28 \pm 9.41 | 28.06 \pm 3.14 | 25.91 \pm 9.28 | 24.71 \pm 10.21 |

Legend: Data are means \pm SD; n(ZDF) = 12/group, arbitrary units normalized to the geometric mean of 18S and Hprt1, and multiplied by 100. ^a p < 0.05 vs. casein (one-way ANOVA). ^b p < 0.05, ^c p < 0.01 vs. chow (one-way ANOVA). ^d p < 0.05, ^e p < 0.01 vs. α -lactalbumin (one-way ANOVA).

Table A3. Gene expression level of selected genes in adipose tissue of ZDF rats after 13 weeks of intervention with milk protein fractions

| Gene | Experimental diet | | | | |
|----------------------------|-------------------------------|---------------------------------|--------------------------------|-------------------------------|--------------------|
| | Isolate | Hydrolysate | α -lactalbumin | Casein | Chow |
| <i>Insulin sensitivity</i> | | | | | |
| IR (InsR) | 0.41 \pm 0.07 | 0.38 \pm 0.09 | 0.42 \pm 0.03 | 0.47 \pm 0.10 ^g | 0.33 \pm 0.08 |
| GLUT4 | 1.32 \pm 0.27 ^g | 1.03 \pm 0.36 ^d | 1.17 \pm 0.31 ^{c,e} | 1.62 \pm 0.18 ^h | 0.77 \pm 0.24 |
| AMPK | 0.26 \pm 0.06 ^b | 0.21 \pm 0.07 ^d | 0.26 \pm 0.06 ^b | 0.36 \pm 0.06 ^h | 0.22 \pm 0.08 |
| Irs1 | 0.46 \pm 0.11 | 0.46 \pm 0.11 | 0.50 \pm 0.09 | 0.45 \pm 0.07 | 0.40 \pm 0.08 |
| Irs2 | 1.35 \pm 0.24 | 1.39 \pm 0.38 | 1.36 \pm 0.24 | 1.51 \pm 0.26 | 1.19 \pm 0.20 |
| AKT | 5.30 \pm 1.17 | 5.00 \pm 1.08 | 5.10 \pm 0.56 | 5.37 \pm 0.81 | 4.69 \pm 1.02 |
| Adipoq | 41.59 \pm 7.06 | 35.39 \pm 12.53 ^c | 40.79 \pm 7.02 | 51.89 \pm 9.25 ^e | 39.75 \pm 10.04 |
| CPT-1 | 0.90 \pm 0.19 | 0.91 \pm 0.22 | 0.90 \pm 0.23 | 0.77 \pm 0.14 | 0.82 \pm 0.19 |
| <i>Inflammation</i> | | | | | |
| IL-6 | 0.02 \pm 0.03 | 0.04 \pm 0.07 | 0.03 \pm 0.08 | 0.01 \pm 0.01 | 0.01 \pm 0.01 |
| TNF- α | 0.02 \pm 0.01 | 0.02 \pm 0.01 | 0.02 \pm 0.01 | 0.02 \pm 0.01 | 0.02 \pm 0.01 |
| <i>Glucose</i> | | | | | |
| GADPH | 13.58 \pm 1.93 ^e | 13.56 \pm 2.50 ^e | 12.67 \pm 1.37 | 12.60 \pm 1.63 | 11.13 \pm 1.93 |
| <i>Transcription</i> | | | | | |
| PPAR- α | 0.15 \pm 0.03 ^a | 0.13 \pm 0.05 ^b | 0.16 \pm 0.06 | 0.20 \pm 0.04 ^e | 0.14 \pm 0.04 |
| PPAR- γ | 1.68 \pm 0.28 ^f | 1.49 \pm 0.42 | 1.48 \pm 0.20 | 1.70 \pm 0.35 ^f | 1.20 \pm 0.24 |
| JNK | 2.17 \pm 0.32 | 2.06 \pm 0.43 | 2.18 \pm 0.24 | 2.29 \pm 0.34 ^e | 1.80 \pm 0.38 |
| SREBP-1C | 1.91 \pm 0.39 | 1.88 \pm 0.64 | 1.85 \pm 0.81 | 2.10 \pm 0.47 ^e | 1.36 \pm 0.46 |
| SREBP-2 | 0.82 \pm 0.19 | 0.77 \pm 0.18 | 0.81 \pm 0.16 | 0.70 \pm 0.12 | 0.77 \pm 0.21 |
| <i>Fat</i> | | | | | |
| FAS | 0.25 \pm 0.88 ^d | 1.46 \pm 0.49 ^d | 2.18 \pm 0.87 ^d | 4.09 \pm 1.11 ^h | 1.58 \pm 0.79 |
| LPL | 124.90 \pm 18.44 | 102.50 \pm 31.43 ^b | 121.50 \pm 16.34 | 140.20 \pm 14.32 | 103.10 \pm 24.50 |
| LXR | 3.28 \pm 0.37 ^f | 3.11 \pm 0.58 | 3.27 \pm 0.34 ^e | 3.36 \pm 0.41 ^f | 2.64 \pm 0.51 |

Legend: Data are means \pm SD; n(ZDF) = 12/group, arbitrary units normalized to the geometric mean of 18S and Hprt1, and multiplied by 100. ^a p < 0.05, ^b p < 0.01, ^c p < 0.001, ^d p < 0.0001 vs. casein (one-way ANOVA). ^e p < 0.05, ^f p < 0.01, ^g p < 0.001, ^h p < 0.0001 vs. chow (one-way ANOVA).

Table A4. Gene expression level of selected genes in liver tissue of Wistar rats after 13 weeks of intervention with milk protein fractions

| Gene | Experimental diet | | | | |
|----------------------------|-------------------|-------------------|-----------------------|------------------------------|------------------|
| | Isolate | Hydrolysate | α -lactalbumin | Casein | Chow |
| <i>Insulin sensitivity</i> | | | | | |
| InsR | 0.30 \pm 0.11 | 0.30 \pm 0.19 | 0.34 \pm 0.14 | 0.29 \pm 0.010 | 0.26 \pm 0.07 |
| GLUT2 | 4.61 \pm 1.48 | 4.99 \pm 2.44 | 5.59 \pm 1.34 | 4.27 \pm 1.76 | 4.78 \pm 1.05 |
| CPT-1 | 4.31 \pm 1.57 | 4.36 \pm 1.94 | 4.51 \pm 1.65 | 3.82 \pm 1.23 | 4.27 \pm 0.65 |
| Irs1 | 0.20 \pm 0.06 | 0.22 \pm 0.13 | 0.22 \pm 0.12 | 0.18 \pm 0.06 | 0.16 \pm 0.03 |
| Irs2 | 0.42 \pm 0.26 | 0.25 \pm 0.06 | 0.29 \pm 0.15 | 0.31 \pm 0.17 | 0.44 \pm 0.17 |
| AKT | 1.05 \pm 0.31 | 4.57 \pm 9.85 | 1.09 \pm 0.35 | 0.92 \pm 0.22 | 1.22 \pm 0.13 |
| AMPK | 1.22 \pm 0.41 | 1.15 \pm 0.53 | 1.27 \pm 0.38 | 1.15 \pm 0.33 | 1.03 \pm 0.25 |
| AdipoqR | 0.37 \pm 0.12 | 0.45 \pm 0.25 | 0.47 \pm 0.20 | 0.39 \pm 0.11 | 0.41 \pm 0.07 |
| <i>Inflammation</i> | | | | | |
| CRP | 23.29 \pm 4.49 | 28.62 \pm 11.25 | 32.66 \pm 7.17 | 23.34 \pm 5.18 | 26.62 \pm 6.12 |
| <i>Glucose</i> | | | | | |
| GYS2 | 1.01 \pm 0.42 | 1.04 \pm 0.56 | 1.02 \pm 0.32 | 0.90 \pm 0.44 | 1.44 \pm 0.70 |
| GADPH | 7.08 \pm 1.34 | 6.88 \pm 3.10 | 8.25 \pm 3.16 | 6.33 \pm 2.23 | 6.09 \pm 1.56 |
| G6Pase | 7.88 \pm 3.88 | 7.75 \pm 4.06 | 8.91 \pm 7.42 | 7.36 \pm 1.49 | 7.52 \pm 3.64 |
| PDK4 | 0.40 \pm 0.25 | 0.29 \pm 0.14 | 0.36 \pm 0.31 | 0.26 \pm 0.20 | 0.48 \pm 0.21 |
| SDH | 5.60 \pm 1.22 | 5.10 \pm 2.31 | 6.26 \pm 1.80 | 5.67 \pm 1.53 | 4.87 \pm 0.44 |
| <i>Transcription</i> | | | | | |
| PGC-1 α | 0.02 \pm 0.01 | 0.01 \pm 0.01 | 0.02 \pm 0.01 | 0.02 \pm 0.01 | 0.01 \pm 0.01 |
| SREBP-1C | 0.58 \pm 0.20 | 0.76 \pm 0.41 | 0.67 \pm 0.32 | 0.66 \pm 0.43 | 0.40 \pm 0.18 |
| SREBP-2 | 0.31 \pm 0.05 | 0.44 \pm 0.25 | 0.33 \pm 0.13 | 0.23 \pm 0.09 ^a | 0.40 \pm 0.11 |
| PPAR- α | 1.34 \pm 0.54 | 1.10 \pm 0.71 | 1.26 \pm 0.59 | 1.26 \pm 0.51 | 1.11 \pm 0.35 |
| PPAR- γ | 0.01 \pm 0.01 | 0.02 \pm 0.01 | 0.02 \pm 0.01 | 0.01 \pm 0.01 | 0.01 \pm 0.00 |
| JNK | 0.60 \pm 0.17 | 0.65 \pm 0.30 | 0.74 \pm 0.26 | 0.59 \pm 0.17 | 0.61 \pm 0.10 |
| <i>Fat</i> | | | | | |
| FAS | 0.12 \pm 0.08 | 0.16 \pm 0.11 | 0.13 \pm 0.09 | 0.07 \pm 0.05 | 0.07 \pm 0.04 |
| LPL | 0.04 \pm 0.03 | 0.07 \pm 0.04 | 0.06 \pm 0.05 | 0.05 \pm 0.02 | 0.08 \pm 0.04 |
| LXR | 1.75 \pm 0.44 | 2.30 \pm 1.11 | 2.33 \pm 0.62 | 1.98 \pm 0.58 | 1.65 \pm 0.41 |

Legend: Data are means \pm SD; n(Wistar) = 8-9/group, arbitrary units normalized to the geometric mean of 18S and Hprt1, and multiplied by 100. ^a p < 0.05 vs. Chow (Kruskal-Wallis nonparametric test).

Table A5. Gene expression level of selected genes in muscle tissue of Wistar rats after 13 weeks of intervention with milk protein fractions

| Gene | Experimental diet | | | | |
|----------------------------|------------------------------|------------------------------|-----------------------|--------------------|--------------------|
| | Isolate | Hydrolysate | α -lactalbumin | Casein | Chow |
| <i>Insulin sensitivity</i> | | | | | |
| AdipoqR | 1.48 \pm 0.48 | 1.52 \pm 0.48 | 1.43 \pm 0.61 | 1.57 \pm 0.92 | 1.56 \pm 0.48 |
| IR (InsR) | 0.55 \pm 0.18 | 0.54 \pm 0.12 | 0.50 \pm 0.15 | 0.54 \pm 0.16 | 0.62 \pm 0.15 |
| Irs1 | 0.53 \pm 0.29 | 0.73 \pm 0.34 | 0.47 \pm 0.14 | 0.52 \pm 0.16 | 0.46 \pm 0.04 |
| Irs2 | 3.05 \pm 2.22 | 2.00 \pm 0.86 | 2.68 \pm 1.48 | 3.60 \pm 3.22 | 1.95 \pm 0.84 |
| AKT | 5.47 \pm 0.97 | 5.37 \pm 0.87 | 5.28 \pm 0.93 | 6.84 \pm 5.26 | 6.23 \pm 0.83 |
| GLUT4 | 13.25 \pm 3.08 | 11.48 \pm 1.86 | 11.99 \pm 2.16 | 18.37 \pm 12.70 | 11.39 \pm 2.15 |
| AMPK | 3.69 \pm 1.58 | 3.71 \pm 1.62 | 3.31 \pm 1.51 | 3.66 \pm 1.60 | 3.76 \pm 1.49 |
| CPT-1 | 0.14 \pm 0.03 | 0.15 \pm 0.05 | 0.13 \pm 0.03 | 0.15 \pm 0.07 | 0.17 \pm 0.03 |
| <i>Glucose</i> | | | | | |
| GADPH | 123.30 \pm 60.76 | 125.30 \pm 69.11 | 113.50 \pm 73.25 | 103.10 \pm 63.77 | 108.50 \pm 65.91 |
| PDK4 | 15.02 \pm 7.05 | 10.55 \pm 4.24 | 9.20 \pm 4.58 | 16.00 \pm 10.90 | 12.23 \pm 7.87 |
| SDH | 19.63 \pm 3.06 | 18.51 \pm 2.70 | 18.22 \pm 2.90 | 26.41 \pm 24.21 | 21.25 \pm 4.03 |
| <i>Transcription</i> | | | | | |
| PGC-1 α | 0.54 \pm 0.17 ^a | 0.26 \pm 0.09 | 0.55 \pm 0.35 | 0.46 \pm 0.28 | 0.48 \pm 0.30 |
| PPAR- γ | 0.03 \pm 0.01 | 0.03 \pm 0.01 | 0.03 \pm 0.01 | 0.03 \pm 0.01 | 0.03 \pm 0.00 |
| SREBP-1C | 0.76 \pm 0.41 | 0.83 \pm 0.30 | 0.84 \pm 0.37 | 1.24 \pm 1.35 | 0.68 \pm 0.20 |
| PPAR- α | 0.80 \pm 0.19 | 0.59 \pm 0.16 | 0.67 \pm 0.14 | 0.82 \pm 0.26 | 0.79 \pm 0.14 |
| JNK | 1.09 \pm 0.19 | 1.01 \pm 0.19 ^b | 1.02 \pm 0.18 | 1.13 \pm 0.44 | 1.32 \pm 0.15 |
| SREBP-2 | 0.30 \pm 0.05 | 0.29 \pm 0.04 | 0.30 \pm 0.04 | 0.38 \pm 0.33 | 0.27 \pm 0.07 |
| <i>Fat</i> | | | | | |
| LXR | 0.21 \pm 0.09 | 0.21 \pm 0.08 | 0.17 \pm 0.07 | 0.20 \pm 0.08 | 0.20 \pm 0.16 |
| FAS | 0.03 \pm 0.02 | 0.03 \pm 0.01 | 0.03 \pm 0.01 | 0.04 \pm 0.02 | 0.03 \pm 0.01 |
| LPL | 26.44 \pm 15.32 | 26.14 \pm 16.84 | 25.89 \pm 12.48 | 39.52 \pm 29.46 | 32.30 \pm 13.52 |

Legend: Data are means \pm SD; n(Wistar) = 8-9/group, arbitrary units normalized to the geometric mean of 18S and Hprt1, and multiplied by 100. ^a p < 0.01 vs. hydrolysate (Kruskal-Wallis nonparametric test). ^b p < 0.05 vs. chow (Kruskal-Wallis nonparametric test).

Table A6. Gene expression level of selected genes in adipose tissue of Wistar rats after 13 weeks of intervention with milk protein fractions

| Gene | Experimental diet | | | | |
|----------------------------|--------------------|--------------------|------------------------------|--------------------------------|--------------------|
| | Isolate | Hydrolysate | α -lactalbumin | Casein | Chow |
| <i>Insulin sensitivity</i> | | | | | |
| IR (InsR) | 0.58 \pm 0.15 | 0.51 \pm 0.12 | 0.48 \pm 0.09 | 0.58 \pm 0.14 | 0.62 \pm 0.11 |
| GLUT4 | 2.29 \pm 1.12 | 2.02 \pm 0.84 | 2.89 \pm 1.10 ^c | 3.77 \pm 2.20 ^d | 1.34 \pm 0.47 |
| AMPK | 0.31 \pm 0.05 | 0.29 \pm 0.07 | 0.32 \pm 0.08 | 0.32 \pm 0.09 | 0.23 \pm 0.05 |
| Irs1 | 0.84 \pm 0.29 | 0.78 \pm 0.23 | 0.76 \pm 0.22 | 0.76 \pm 0.22 | 1.03 \pm 0.27 |
| Irs2 | 2.72 \pm 0.87 | 2.23 \pm 0.58 | 2.15 \pm 0.63 | 2.15 \pm 0.77 | 2.47 \pm 0.29 |
| AKT | 6.11 \pm 0.91 | 6.47 \pm 1.26 | 5.86 \pm 1.04 | 5.70 \pm 1.20 | 7.01 \pm 1.10 |
| Adipoq | 82.97 \pm 14.37 | 78.57 \pm 8.98 | 84.44 \pm 15.45 | 77.13 \pm 11.02 | 83.47 \pm 11.74 |
| CPT-1 | 0.40 \pm 0.08 | 0.38 \pm 0.10 | 0.31 \pm 0.08 ^b | 0.34 \pm 0.09 ^a | 0.47 \pm 0.06 |
| <i>Inflammation</i> | | | | | |
| TNF- α | 0.01 \pm 0.00 | 0.01 \pm 0.00 | 0.00 \pm 0.00 | 0.01 \pm 0.00 | 0.01 \pm 0.00 |
| <i>Glucose</i> | | | | | |
| GADPH | 10.19 \pm 2.71 | 10.74 \pm 2.51 | 11.43 \pm 3.48 | 14.93 \pm 8.53 | 7.87 \pm 1.17 |
| PDK4 | 1.62 \pm 0.67 | 1.19 \pm 0.38 | 1.37 \pm 0.71 | 1.38 \pm 0.73 | 1.47 \pm 0.46 |
| SDH | 9.63 \pm 1.56 | 9.50 \pm 1.90 | 8.96 \pm 0.70 | 10.10 \pm 2.26 | 8.67 \pm 1.35 |
| <i>Transcription</i> | | | | | |
| PGC-1 α | 0.01 \pm 0.00 | 0.01 \pm 0.01 | 0.01 \pm 0.00 | 0.01 \pm 0.00 | 0.01 \pm 0.01 |
| PPAR- α | 0.24 \pm 0.08 | 0.21 \pm 0.02 | 0.22 \pm 0.04 | 0.24 \pm 0.04 | 0.20 \pm 0.04 |
| PPAR- γ | 2.10 \pm 0.46 | 2.05 \pm 0.39 | 1.86 \pm 0.43 | 2.16 \pm 0.23 | 2.28 \pm 0.43 |
| JNK | 1.64 \pm 0.26 | 1.62 \pm 0.27 | 1.65 \pm 0.26 | 1.65 \pm 0.29 | 1.69 \pm 0.22 |
| SREBP-1C | 4.06 \pm 1.36 | 4.40 \pm 0.82 | 4.49 \pm 0.93 | 4.86 \pm 1.03 | 4.22 \pm 0.97 |
| SREBP-2 | 0.44 \pm 0.06 | 0.42 \pm 0.07 | 0.44 \pm 0.05 | 0.45 \pm 0.07 | 0.45 \pm 0.05 |
| <i>Fat</i> | | | | | |
| FAS | 6.47 \pm 3.64 | 6.02 \pm 3.83 | 12.85 \pm 8.78 | 20.97 \pm 18.25 ^c | 4.08 \pm 2.60 |
| LPL | 160.10 \pm 34.27 | 151.60 \pm 31.41 | 160.80 \pm 32.62 | 127.40 \pm 26.68 | 151.20 \pm 26.17 |
| LXR | 3.85 \pm 0.73 | 3.72 \pm 0.73 | 3.62 \pm 0.58 | 3.78 \pm 0.57 | 3.48 \pm 0.61 |

Legend: Data are means \pm SD; n(Wistar) = 8-9/group, arbitrary units normalized to the geometric mean of 18S and Hprt1, and multiplied by 100. ^a p < 0.05, ^b p < 0.01 vs. chow (one-way ANOVA). ^c p < 0.05, ^d p < 0.01 vs. chow (Kruskal-Wallis nonparametric test).

■ References

1. **Graf S, Egert S, Heer M.** Effects of whey protein supplements on metabolism: evidence from human intervention studies. *Curr Opin Clin Nutr Metab Care* 2011. 14:569-580.
2. **Jakubowicz D, Froy O.** Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and type 2 diabetes. *J Nutr Biochem* 2013. 24:1-5.
3. **Petersen BL, Ward LS, Bastian ED, Jenkins AL, Campbell J, Vuksan V.** A whey protein supplement decreases post-prandial glycemia. *Nutr J* 2009. 8:47.
4. **Luhovyy BL, Akhavan T, Anderson GH.** Whey proteins in the regulation of food intake and satiety. *J Am Coll Nutr* 2007. 26:704S-712S.
5. **Holmer-Jensen J, Mortensen LS, Astrup A, de Vrese M, Holst JJ, Thomsen C, Hermansen K.** Acute differential effects of dietary protein quality on postprandial lipemia in obese non-diabetic subjects. *Nutr Res* 2013. 33:34-40.
6. **Mortensen LS, Hartvigsen ML, Brader LJ, Astrup A, Schrezenmeir J, Holst JJ, Thomsen C, Hermansen K.** Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. *Am J Clin Nutr* 2009. 90:41-48.
7. **Krissansen GW.** Emerging health properties of whey proteins and their clinical implications. *J Am Coll Nutr* 2007. 26:713S-723S.
8. **Unger RH.** How obesity causes diabetes in Zucker diabetic fatty rats. *Trends Endocrinol Metab* 1997. 8:276-282.
9. **Matthews JN, Altman DG, Campbell, MJ, Royston P.** Analysis of serial measurements in medical research. *BMJ* 1990. 300:230-235.
10. **Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP.** Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. *Am J Physiol Endocrinol Metab* 2008. 295:E1269-E1276.
11. **Fitzgerald RJ, Murray BA, Walsh DJ.** Hypotensive peptides from milk proteins. *J Nutr* 2004. 134:980S-988S.
12. **Tulipano G, Sibilia V, Caroli AM, Cocchi D.** Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. *Peptides* 2011. 32:835-838.
13. **Pal S, Ellis V.** The acute effects of four protein meals on insulin, glucose, appetite and energy intake in lean men. *Br J Nutr* 2010. 104:1241-1248.
14. **Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM.** Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. *Am J Clin Nutr* 2004. 80:1246-1253.
15. **Tessari P, Kiwanuka E, Cristini M, Zaramella M, Enslin M, Zurlo C, Garcia-Rodenas C.** Slow versus fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2 diabetes. *Diabetes Metab Res Rev* 2007. 23:378-385.
16. **Shertzer HG, Woods SE, Krishan M, Genter MB, Pearson KJ.** Dietary whey protein lowers the risk for metabolic disease in mice fed a high-fat diet. *J Nutr* 2011. 141:582-587.
17. **Pal S, Ellis V, Dhaliwal S.** Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. *Br J Nutr* 2010. 104:716-723.
18. **Ma J, Stevens JE, Cukier K, Maddox AF, Wishart JM, Jones KL, Clifton PM, Horowitz M, Rayner CK.** Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. *Diabetes Care* 2009. 32:1600-1602.
19. **Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH.** Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. *Am J Clin Nutr* 2010. 91:966-975.
20. **Van Dael P, Kastenmayer P, Clough J, Jarret AR, Barclay DV, Maire JC.** Substitution of casein by beta-casein or of whey protein isolate by alpha-lactalbumin does not affect mineral balance in growing rats. *J Nutr* 2005. 135:1438-1443.
21. **Haraguchi FK, Pedrosa ML, Paula H, Santos RC, Silva ME.** Evaluation of biological and biochemical quality of whey protein. *J Med Food* 2010. 13:1505-1509.
22. **Bultot L, Guigas B, Von Wilamowitz-Moellendorf A, Maisin L, Vertommen D, Hussain N, Beullens M, Guinovart JJ, Foretz M, et al.** AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. *Biochem J* 2012. 443:193-203.
23. **Unger RH, Cherrington AD.** Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. *J Clin Invest* 2012. 122:4-12.
24. **Hermansen K.** Characterisation of the abnormal pancreatic D and A cell function in streptozotocin diabetic dogs: studies with D-glyceraldehyde, dihydroxyacetone, D-mannoheptulose, D-glucose, and L-arginine. *Diabetologia* 1981. 21:489-494.
25. **Solinas G, Karin M.** JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. *FASEB J* 2010. 24:2596-2611.
26. **Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS.** A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. *PLoS One* 2008. 3:e3151.
27. **Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF.** Adiponectin and protection against type 2 diabetes mellitus. *Lancet* 2003. 361:226-228.
28. **Claessens M, van Baak MA, Monsheimer S, Saris WH.** The effect of a low-fat, high-protein or high-carbohydrate ad libitum diet on weight loss maintenance and metabolic risk factors. *Int J Obes (Lond)* 2009. 33:296-304.